These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 10898351)

  • 1. Current and future directions in medical therapy: hypercalcemia.
    Body JJ
    Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-finding study of zoledronate in hypercalcemic cancer patients.
    Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
    J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical research update: zoledronate.
    Body JJ
    Cancer; 1997 Oct; 80(8 Suppl):1699-701. PubMed ID: 9362440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and convenience of a 15-minute infusion of zoledronic acid.
    Berenson J; Hirschberg R
    Oncologist; 2004; 9(3):319-29. PubMed ID: 15169987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hypercalcemia of malignancy with bisphosphonates.
    Berenson JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercalcemia of malignancy.
    Body JJ
    Semin Nephrol; 2004 Jan; 24(1):48-54. PubMed ID: 14730509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
    Major P
    Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.
    Heatley S
    Int J Palliat Nurs; 2001 Jun; 7(6):301-2, 304-7. PubMed ID: 12066026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current management strategies for hypercalcemia.
    Pecherstorfer M; Brenner K; Zojer N
    Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
    Body JJ; Louviaux I; Dumon JC
    Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates: biological response modifiers in breast cancer.
    Paterson AH
    Clin Breast Cancer; 2002 Aug; 3(3):206-16; discussion 217-8. PubMed ID: 12196279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
    Body JJ; Bartl R; Burckhardt P; Delmas PD; Diel IJ; Fleisch H; Kanis JA; Kyle RA; Mundy GR; Paterson AH; Rubens RD
    J Clin Oncol; 1998 Dec; 16(12):3890-9. PubMed ID: 9850035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia.
    Atula ST; Tähtelä RK; Nevalainen JI; Pylkkänen LH
    Acta Oncol; 2003; 42(7):735-40. PubMed ID: 14690159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates in breast cancer.
    Coleman RE
    Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
    Coleman RE
    Oncology (Williston Park); 1991 Aug; 5(8):55-60; discussion 60-2, 65. PubMed ID: 1834153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates and breast carcinoma.
    Lipton A
    Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
    Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.